About: Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.44 (-6.49%)
CRBUNASDAQCaribou Biosciences Inc
Caribou Biosciences Inc share price
CRBU price activity
Last Price
$1.440
Change (24hr)
-0.10 USD (-6.49%)
Volume
1.75M
Volume (4w avg)
-
Open
$1.53
Day Range
$1.44 - $1.54
Previous Close
$1.54
Last Trade
09 Sep, 8:10 pm GMT+0
Delayed
09 Sep, 8:10 pm GMT+0
CRBU price performance
Delayed
09 Sep, 8:10 pm GMT+0
CRBU Market Signals